XIN 주식 개요 산동 신화 제약 유한회사는 자회사를 통해 중화인민공화국, 미주, 유럽 및 국제적으로 벌크 의약품, 제제 및 화학 원료를 개발, 제조 및 판매합니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Shandong Xinhua Pharmaceutical Company Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Shandong Xinhua Pharmaceutical 과거 주가 현재 주가 HK$0.69 52주 최고치 HK$0.89 52주 최저치 HK$0.55 베타 -0.019 1개월 변경 4.51% 3개월 변경 사항 16.81% 1년 변경 사항 11.20% 3년 변화 37.62% 5년 변화 68.69% IPO 이후 변화 903.90%
최근 뉴스 및 업데이트
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) signed an equity acquisition intention agreement to acquire 75% stake in Novosana (Taicang) Bio Feed Co., Ltd. from Novosana (Europe) B.V. Dec 12
Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation Nov 05
Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023) Oct 29
Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application Oct 28
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024 Sep 21 더 많은 업데이트 보기
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) signed an equity acquisition intention agreement to acquire 75% stake in Novosana (Taicang) Bio Feed Co., Ltd. from Novosana (Europe) B.V. Dec 12
Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation Nov 05
Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023) Oct 29
Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application Oct 28
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024 Sep 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application Sep 13
Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs Sep 02
Upcoming dividend of HK$0.027 per share Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2023) Aug 23
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024 Aug 22
Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024 Jul 24
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024 Jun 29
Dividend of HK$0.27 announced Jun 28
Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024 Jun 26
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024 May 29
First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023) Apr 26
Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024 Mar 30
Full year 2023 earnings released: EPS: CN¥0.74 (vs CN¥0.62 in FY 2022) Mar 29
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023 Mar 28
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient Feb 28
Now 21% overvalued Jan 26
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate Jan 19
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024 Dec 30
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes Dec 26
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg) Dec 15
Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2022) Oct 29
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat Oct 11
Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration Aug 12
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee Jul 27
Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023 Jul 22 Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation Jul 15
Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation Jul 11
Upcoming dividend of HK$0.22 per share at 3.7% yield Jun 30
Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs Jun 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration Jun 14
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 25
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 24
Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.56 in FY 2021) Mar 25
Investor sentiment deteriorated over the past week Dec 29
Investor sentiment improved over the past week Dec 13
Less than half of directors are independent Nov 16
Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2021) Oct 26
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022 Oct 13
Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes Sep 20
Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 2Q 2021) Aug 31
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022 Aug 19
Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022 Jul 30
Upcoming dividend of HK$0.18 per share Jul 08
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager Jul 04
Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022 Jul 01
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022 Jun 01
Less than half of directors are independent Apr 27
Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021 Apr 01
Full year 2021 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in FY 2020) Mar 31
Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 3Q 2020) Oct 16
Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.14 in 2Q 2020) Aug 30
Shandong Xinhua Pharmaceutical Company Limited announced that it expects to receive CNY 249.999998 million in funding from Hualu Investment Development Co., Ltd. Apr 16
Full year 2020 earnings released: EPS CN¥0.52 (vs CN¥0.48 in FY 2019) Apr 02
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021 Feb 24
New 90-day high: €0.60 Feb 18
New 90-day high: €0.47 Jan 22
Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments Dec 23
New 90-day low: €0.38 Dec 05
Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments Dec 02
Shandong Xinhua Pharmaceutical Company Limited Announces the Retirement of Certain Directors and Supervisors Nov 20
Third quarter earnings released Oct 25
Third quarter earnings released Oct 24
Shandong Xinhua Pharmaceutical Company Limited to Report Nine Months, 2020 Results on Oct 22, 2020 Oct 13
New 90-day low: €0.38 Oct 05
New 90-day low - €0.41 Sep 12
New 90-day low - €0.44 Aug 27
Earnings released Aug 23
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 24, 2020 Aug 01
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) completed the acquisition of 33% stake in Shandong Xinhua Wanbo Chemical Industrial Co., Ltd from Hualu Holding Co., Ltd. Jul 31 주주 수익률 XIN DE Pharmaceuticals DE 마켓 7D 2.2% -2.2% -2.0% 1Y 11.2% -15.6% 6.9%
전체 주주 수익률 보기
수익률 대 산업: XIN 지난 1년 동안 -15.6 %를 반환한 German Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: XIN 지난 1년 동안 6.9 %를 반환한 German 시장을 초과했습니다.
가격 변동성 Is XIN's price volatile compared to industry and market? XIN volatility XIN Average Weekly Movement 8.8% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: XIN 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: XIN 의 주간 변동성 ( 9% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 산동 신화 제약 유한회사는 자회사를 통해 중화인민공화국, 미주, 유럽 및 국제적으로 벌크 의약품, 제제 및 화학 원료를 개발, 제조 및 판매하고 있습니다. 이 회사는 해열제 및 진통제, 심혈관 및 뇌혈관 약물, 항감염제 및 중추신경계, 신경계 약물, 기타 약물을 제공합니다. 부동산 사업 개발에도 참여하고 있습니다.
자세히 보기 Shandong Xinhua Pharmaceutical Company Limited 기본 사항 요약 Shandong Xinhua Pharmaceutical 의 수익과 매출은 시가총액과 어떻게 비교하나요? XIN 기본 통계 시가총액 €1.19b 수익(TTM ) €58.93m 수익(TTM ) €1.10b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) XIN 손익 계산서(TTM ) 수익 CN¥8.34b 수익 비용 CN¥6.32b 총 이익 CN¥2.01b 기타 비용 CN¥1.56b 수익 CN¥448.62m
주당 순이익(EPS) 0.66 총 마진 24.15% 순이익 마진 5.38% 부채/자본 비율 32.5%
XIN 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/23 06:09 장 마감 주가 2024/12/20 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Shandong Xinhua Pharmaceutical Company Limited 3 애널리스트 중 0 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Alex Fan GF Securities (Hong Kong) Brokerage Limited Ming Li Industrial Securities Co. Ltd. Guohe Fan Phillip Securities (HK)
0 더 많은 분석가 보기 
